What is it about?
Coronary artery disease (CAD) and acute myocardial infarction (AMI) are the leading causes of death worldwide. Circulating microRNAs represent diagnostic powerful biomarkers for detection of heart injuries and patients’ risk stratification. After a profiling of the most common circulating miRNAs in these patients, we focused our attention on the differential expression of miR-423-5p suggesting its potential use as an epigenetic biomarker for risk stratification of CAD patients.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Only a subset of CAD patients develops myocardial infarction (MI), consequently it is likely that unique factors predispose to AMI. This pilot-study is aimed to compare the differences in circulating miRNAs’ expression between patients with stable CAD and patients with AMI; therefore, we did not consider healthy subjects. We found a lower expression level of miR-423-5p in CAD patients within 24 hours from the AMI event. The expression value of miR-423-5p increase in the same patients 6 months post-AMI. MiR-423-5p expression level both in plasma and blood cells, could represent a new promising biomarker for risk stratification of CAD patients.
Perspectives
MiR-423-5p expression level demonstrated a good discriminatory ability to separate stable elder CAD patients from patients with AMI. Our study confirms the need of deeper investigations on miR-423-5p as a new epigenetic biomarker with diagnostic and, hopefully in future, prognostic value.
FRANCESCA AMATI
Universita degli Studi di Roma Tor Vergata
Read the Original
This page is a summary of: MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: A pilot study, PLoS ONE, May 2019, PLOS,
DOI: 10.1371/journal.pone.0216363.
You can read the full text:
Contributors
The following have contributed to this page
